Welcome to our dedicated page for Viking Therapeutics news (Ticker: VKTX), a resource for investors and traders seeking the latest updates and insights on Viking Therapeutics stock.
Viking Therapeutics, Inc. develops clinical-stage biopharmaceutical therapies for metabolic and endocrine disorders. News about VKTX centers on VK2735, a dual GLP-1 and GIP receptor agonist being developed in subcutaneous and oral formulations for obesity and other metabolic disorders, including updates from the VANQUISH and VENTURE clinical programs.
Recurring company updates also cover financial results, corporate development, investor-conference participation, and earlier pipeline work such as an amylin agonist program. Viking's announcements typically connect clinical trial design, efficacy and safety data, regulatory interactions, and cash resources to the progress of its metabolic-disease portfolio.
Viking Therapeutics announced positive results from its Phase 1b clinical trial of VK0214, a novel TRβ agonist, in patients with X-linked adrenoleukodystrophy (X-ALD). The study showed VK0214 to be safe and well-tolerated with once-daily dosing over 28 days. Significant reductions were observed in plasma levels of very long-chain fatty acids (VLCFAs) and other lipids compared to placebo.
Key findings include:
- Significant reductions in mean VLCFA levels at both 20 mg/day and 40 mg/day doses
- Reductions in C26:0-LPC, a key diagnostic marker
- Decreases in LDL-C, ApoB, and Lp(a) levels
- Mild to moderate treatment emergent adverse events
- Lower incidence of gastrointestinal adverse events in VK0214-treated subjects (11%) compared to placebo (33%)
The company views these results as encouraging and plans to explore next steps for VK0214 in X-ALD treatment.
Viking Therapeutics (NASDAQ: VKTX) announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference from September 4-6, 2024, in New York City. CEO Brian Lian, Ph.D., will be the featured speaker in a fireside chat scheduled for September 4, 2024, from 1:50 – 2:25 p.m. Eastern at the New York Marriott Marquis.
The event will include Dr. Lian's participation in 1-on-1 meetings and a live webcast of the fireside chat. Investors can access the webcast through Viking's website in the Investors & Media section under Webcasts. A replay will be available post-conference. Viking Therapeutics is a clinical-stage biopharmaceutical company focusing on developing novel therapies for metabolic and endocrine disorders.
Viking Therapeutics (NASDAQ: VKTX) reported Q2 2024 financial results and provided corporate updates.
Key points include:
- VK2735: Advancing to Phase 3 for obesity after successful Phase 2 outcomes; Phase 2 oral study to begin in Q4 2024.
- VK2809: Positive biopsy results in NASH/MASH; End-of-Phase 2 meeting planned for Q4 2024.
- VK0214: Phase 1b study completed enrollment for X-ALD; data expected in H2 2024.
- Financials: Net loss of $22.3M ($0.20 per share) in Q2 2024 versus $19.2M ($0.19 per share) in Q2 2023. Cash and equivalents at $942M as of June 30, 2024.
Viking will host a conference call at 4:30 p.m. ET today to discuss these results.
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focusing on novel therapies for metabolic and endocrine disorders, has announced its plans to release financial results for the second quarter of 2024 after market close on July 24, 2024. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the financial results and provide general corporate updates.
Interested parties can participate in the conference call by dialing (844) 850-0543 from the U.S. or (412) 317-5199 from outside the U.S. A telephone replay will be available until July 31, 2024. The call can also be accessed via webcast on Viking's website, with an archive available for 30 days.
Viking Therapeutics (NASDAQ: VKTX) presented preclinical data on its novel dual amylin and calcitonin receptor agonists (DACRAs) at the 84th Scientific Sessions of the American Diabetes Association. The studies showcased significant reductions in body weight and food intake in healthy rats and diet-induced obese (DIO) mice, with improvements in key metabolic markers such as blood glucose levels.
Viking's DACRAs achieved up to 8% body weight reduction in lean rats 72 hours post a single dose, and up to 10% weight loss in DIO mice over 24 days. Additionally, a 24% reduction in blood glucose was observed in DIO mice after 24 days. The compounds demonstrated EC50 values ranging from low nM to micromolar on the human amylin 3 and calcitonin receptors. These results support the continued development of Viking's dual agonist program targeting obesity and metabolic diseases.
Viking Therapeutics has announced positive 52-week histologic data from its Phase 2b VOYAGE study of VK2809 in patients with biopsy-confirmed NASH. VK2809 demonstrated significant efficacy across key endpoints: up to 75% of treated patients achieved NASH resolution with no worsening of fibrosis, and up to 57% showed a ≥1-stage improvement in fibrosis without worsening of NASH. The safety profile was consistent with earlier results, with most adverse events being mild or moderate. The results also showed substantial reductions in liver fat content and plasma lipids, indicating potential cardio-protective benefits.
Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine disorders, announced participation in two upcoming investor conferences.
At the 2024 Jefferies Global Healthcare Conference, Viking will deliver a corporate presentation and engage in 1-on-1 meetings on June 5-6, 2024, at the Marriott Marquis, New York. The presentation is scheduled for June 6, 2024, from 10:30 to 10:55 a.m. Eastern.
Viking will also participate in 1-on-1 meetings at the Stifel 2nd European Healthcare Summit from June 25-27, 2024, at the InterContinental Lyon Hotel Dieu, Lyon, France.
A live webcast of the Jefferies presentation will be available on Viking’s website, with a replay accessible following the conference.
Summary not available.
Summary not available.
Summary not available.